par Lotstra, Françoise 
;Lestienne, Séverine ;De Nayer, Andre
Référence Revue médicale de Bruxelles, 31, 4, page (226-230)
Publication Publié, 2010-09
;Lestienne, Séverine ;De Nayer, AndreRéférence Revue médicale de Bruxelles, 31, 4, page (226-230)
Publication Publié, 2010-09
Article révisé par les pairs
| Résumé : | Antipsychotics play a key role in biologic therapy of schizophrenia. Following the first-generation neuroleptics, associated with many extrapyramidal side effects (severe dystonias, parkinsonian syndrome, akatisia and late dyskinesia) altering patients' compliance to the treatment, one can now find a new generation of molecules considered as atypical antipsychotics because they rarely cause neurological complications. This propriety provides a better compliance, along with a clear decrease of late dyskinesia risk but the effectiveness compared to ordinary molecules is still questioned. However, some of them can cause an increased risk of metabolic syndrome. Some molecules such as benzodiazepines and some antidepressants can also be prescribed to cure schizophrenic patients. |
